A retrospective analysis in Japan found that adverse event reports for DPP-4 inhibitor-associated pemphigoid rose following regulatory package insert updates, then declined after the immediate period. The study frames the pattern as an evidence of how label revisions can rapidly change pharmacovigilance reporting behavior. Clinically, pemphigoid is an established immune-mediated dermatologic adverse event and ongoing pharmacovigilance is central for risk communication and prescribing decisions. For regulators and safety teams, the work underscores the need to interpret spontaneous reporting spikes carefully, separating real risk changes from awareness-driven reporting effects.